Navigation Links
Oncothyreon announces closing of $11.1 million registered direct financing
Date:5/27/2009

SEATTLE, May 27 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX: ONY) announced today that it closed its previously announced sale of 3,878,993 shares of its common stock and warrants to purchase 2,909,244 shares of its common stock for gross proceeds of approximately $11.1 million on May 26, 2009. Oncothyreon sold the shares and warrants for $2.85 per unit (each unit consisting of one share and a warrant to purchase 0.75 shares of common stock). The exercise price of the warrants is $3.92 per share. The warrants will be exercisable at any time on or after the six-month anniversary and on or prior to the fifth anniversary of the closing of the transaction on May 26, 2009. Oncothyreon plans to use the proceeds from this financing for general corporate purposes. Boenning & Scattergood, Inc. acted as exclusive placement agent in the transaction.

A registration statement relating to these securities (File # 333-149837) has been declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor, shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Any offer of these securities will be solely by means of a prospectus included in the registration statement and any prospectus supplement that may be issued with respect to such offering. Copies of the final prospectus, including the prospectus supplement, can be obtained at the Securities and Exchange Commission's website, www.sec.gov, from Oncothyreon at its Seattle, Washington address below or Boenning & Scattergood, Inc. by calling 1-800-883-1212.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer.


'/>"/>
SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Oncothyreon announces commitments to purchase $11.1 million of company securities in a registered direct financing
2. Oncothyreons PX-866 is effective in preclinical model of pulmonary fibrosis
3. Oncothyreon announces presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
4. Oncothyreon reports first quarter 2009 financial results
5. Oncothyreon regains compliance with NASDAQ listing requirements
6. Oncothyreon to present at Invest Northwest 2009
7. Oncothyreon reports full year and fourth quarter 2008 financial results
8. Oncothyreon announces webcast of fourth quarter and year end 2008 financial results conference call
9. Oncothyreon to present at BIO CEO & Investor Conference 2009
10. Oncothyreon reports third quarter 2008 financial results
11. Oncothyreon to present at Rodman & Renshaw Annual Global Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... In a list published by the Boston ... 76 fastest-growing private companies; a small percentage of the state's 615,000+ small businesses. The ... percent change in revenue from 2012 to 2015. , As this award ...
(Date:5/3/2016)... May 3, 2016 - And ... and Producers of Those Competitor Biologics  - ... Activities and Prospects ,  Who are the ... And what are their sales potentials? Discover, in our ... results, trends, opportunities and revenue forecasting. ...
(Date:5/2/2016)... ... May 02, 2016 , ... Meister Media ... the fresh look and added functionality give the agricultural world a taste of ... dynamic shift in agriculture – from precision farming via satellites and Unmanned Aerial ...
(Date:4/29/2016)... ... April 29, 2016 , ... Amendia, Inc., ... surgical procedures, today announced the completion of a significant transaction and partnership that ... future customers and partners. Kohlberg & Company, L.L.C. (“Kohlberg”), a leading private ...
Breaking Biology Technology:
(Date:3/15/2016)... March 15, 2016 Yissum Research Development ... technology-transfer company of the Hebrew University, announced today the ... sensing technology of various human biological indicators. Neteera Technologies ... million from private investors. ... the detection of electromagnetic emissions from sweat ducts, enables ...
(Date:3/10/2016)... , March 10, 2016 ... new market research report "Identity and Access Management Market ... Audit, Compliance, and Governance), by Organization Size, by Deployment, ... 2020", published by MarketsandMarkets, The market is estimated to ... 12.78 Billion by 2020, at a Compound Annual Growth ...
(Date:3/8/2016)... , March 8, 2016   Valencell , ... today announced it has secured $11M in Series ... Tech, a new venture fund being launched by ... participation from existing investors TDF Ventures and WSJ ... to continue its triple-digit growth and accelerate its ...
Breaking Biology News(10 mins):